vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($199.5M vs $128.6M, roughly 1.6× CorMedix Inc.).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
CRMD vs VRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $199.5M |
| Net Profit | — | $7.1M |
| Gross Margin | 83.4% | — |
| Operating Margin | 46.0% | 7.7% |
| Net Margin | — | 3.6% |
| Revenue YoY | — | -4.1% |
| Net Profit YoY | — | -78.1% |
| EPS (diluted) | $0.20 | $1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $199.5M | ||
| Q4 25 | $128.6M | $208.0M | ||
| Q3 25 | $104.3M | $216.4M | ||
| Q2 25 | $39.7M | $210.5M | ||
| Q1 25 | $39.1M | $217.9M | ||
| Q4 24 | — | $233.5M | ||
| Q3 24 | — | $227.0M | ||
| Q2 24 | — | $224.4M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | — | $33.9M | ||
| Q3 25 | $108.6M | $31.3M | ||
| Q2 25 | $19.8M | $42.7M | ||
| Q1 25 | $20.6M | $28.1M | ||
| Q4 24 | — | $39.5M | ||
| Q3 24 | — | $49.1M | ||
| Q2 24 | — | $26.0M |
| Q1 26 | — | — | ||
| Q4 25 | 83.4% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 95.3% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 7.7% | ||
| Q4 25 | 46.0% | 19.1% | ||
| Q3 25 | 49.2% | 21.7% | ||
| Q2 25 | 49.2% | 21.5% | ||
| Q1 25 | 51.5% | 16.8% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | — | 24.3% | ||
| Q2 24 | — | 19.7% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | — | 16.3% | ||
| Q3 25 | 104.1% | 14.5% | ||
| Q2 25 | 49.9% | 20.3% | ||
| Q1 25 | 52.8% | 12.9% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 21.6% | ||
| Q2 24 | — | 11.6% |
| Q1 26 | — | $1.05 | ||
| Q4 25 | $0.20 | $5.15 | ||
| Q3 25 | $1.26 | $4.65 | ||
| Q2 25 | $0.28 | $6.12 | ||
| Q1 25 | $0.30 | $4.05 | ||
| Q4 24 | — | $4.65 | ||
| Q3 24 | — | $5.71 | ||
| Q2 24 | — | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $136.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.3M | $93.6B |
| Total Assets | $826.1M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $136.6M | ||
| Q4 25 | $148.5M | — | ||
| Q3 25 | $55.7M | — | ||
| Q2 25 | $190.7M | — | ||
| Q1 25 | $77.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $390.0M | ||
| Q3 25 | — | $390.6M | ||
| Q2 25 | — | $231.3M | ||
| Q1 25 | — | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M |
| Q1 26 | — | $93.6B | ||
| Q4 25 | $405.3M | $934.0M | ||
| Q3 25 | $374.1M | $918.7M | ||
| Q2 25 | $220.6M | $896.4M | ||
| Q1 25 | $114.9M | $893.7M | ||
| Q4 24 | — | $897.5M | ||
| Q3 24 | — | $889.0M | ||
| Q2 24 | — | $868.7M |
| Q1 26 | — | — | ||
| Q4 25 | $826.1M | $4.3B | ||
| Q3 25 | $750.9M | $3.9B | ||
| Q2 25 | $252.6M | $3.7B | ||
| Q1 25 | $149.6M | $3.7B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | — | $3.6B | ||
| Q2 24 | — | $3.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | — |
| Free Cash FlowOCF − Capex | $92.7M | — |
| FCF MarginFCF / Revenue | 72.1% | — |
| Capex IntensityCapex / Revenue | 1.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $94.5M | $-67.2M | ||
| Q3 25 | $30.9M | $108.3M | ||
| Q2 25 | $30.0M | $75.8M | ||
| Q1 25 | $19.7M | $-3.8M | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | — | $69.1M | ||
| Q2 24 | — | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $92.7M | $-74.1M | ||
| Q3 25 | $30.4M | $106.9M | ||
| Q2 25 | $30.0M | $74.2M | ||
| Q1 25 | $19.7M | $-6.8M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $68.7M | ||
| Q2 24 | — | $68.6M |
| Q1 26 | — | — | ||
| Q4 25 | 72.1% | -35.6% | ||
| Q3 25 | 29.1% | 49.4% | ||
| Q2 25 | 75.4% | 35.2% | ||
| Q1 25 | 50.5% | -3.1% | ||
| Q4 24 | — | -1.6% | ||
| Q3 24 | — | 30.3% | ||
| Q2 24 | — | 30.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 3.3% | ||
| Q3 25 | 0.5% | 0.7% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | -1.99× | ||
| Q3 25 | 0.28× | 3.45× | ||
| Q2 25 | 1.51× | 1.77× | ||
| Q1 25 | 0.96× | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
